|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
This item is licensed under:Creative Commons Attribution-NonCommercial 4.0 International
| Title: | Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone |
| Authors: | Cho, Kyu Yong Browse this author | | Nakamura, Akinobu Browse this author →KAKEN DB | | Omori, Kazuno Browse this author | | Takase, Takahiro Browse this author | | Miya, Aika Browse this author | | Yamamoto, Kohei Browse this author | | Nomoto, Hiroshi Browse this author →KAKEN DB | | Kameda, Hiraku Browse this author →KAKEN DB | | Taneda, Shinji Browse this author | | Kurihara, Yoshio Browse this author | | Aoki, Shin Browse this author | | Atsumi, Tatsuya Browse this author →KAKEN DB | | Miyoshi, Hideaki Browse this author →KAKEN DB |
| Keywords: | Fatty liver | | Sodium–glucosecotransporter 2 inhibitors | | Type 2diabete |
| Issue Date: | 8-Jul-2021 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Journal of Diabetes Investigation |
| Volume: | 12 |
| Issue: | 7 |
| Start Page: | 1272 |
| End Page: | 1277 |
| Publisher DOI: | 10.1111/jdi.13457 |
| Abstract: | Aims/Introduction Sodium?glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium?glucose cotransporter inhibitors for NAFLD. Materials and Methods In this multicenter, open‐label, prospective, randomized, parallel‐group comparison trial, patients taking pioglitazone for ≥12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and γ‐glutamyl transpeptidase, was used for the evaluation of NAFLD. Results A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 ± 23.4 to 42.1 ± 23.9) compared with the pioglitazone group (49.0 ± 26.1 to 51.1 ± 25.8; P < 0.01). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin (P = 0.03) and insulin level (P < 0.01) in the dapagliflozin group. Conclusion Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control. |
| Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/82892 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|
